The Food and Drug Administration has issued an emergency use authorization (EUA) for COVID-19 convalescent plasma (CCP) as a treatment for patients battling COVID-19. AABB has developed a new toolkit for CCP under FDA’s EUA to assist members in keeping updated on the changing regulatory environment regarding CCP. AABB will update the toolkit based on additional updates.